GlaxoSmithKline
GSK makes record whistleblower payout
October 28, 2010Manufacturing and Production Cheryl Eckard, FDA, GSK, GlaxoSmithKline, manufacturing compliance, whistle blower
GlaxoSmithKline has officially agreed to plead guilty to distributing adulterated drugs made at its now-closed facility in Cidra, Puerto Rico, …
Pharma engages HTA bodies in early-stage drug discussions
October 27, 2010Research and Development, Sales and Marketing Andrew Witty, AstraZeneca, EMA, European Medicines Agency, GlaxoSmithKline, Johnson & Johnson, health technology assessment, hta
Three pharma companies are taking part in a new pilot to harmonise European standards in health technology assessment (HTA). AstraZeneca, …
GSK cleared of unethical practices by PMCPA
October 22, 2010Medical Communications ABPI, ABPI Code of Practice, Avamys, GSK, GlaxoSmithKline, PMCPA, Rupafin, Seretide
GlaxoSmithKline has been found guilty of two transgressions of the ABPI Code of Practice in a case centring on the …
Revenue slump for GSK as Avandia sales stall
October 22, 2010Sales and Marketing Avandia, GSK, GlaxoSmithKline, UK science budget, patent box, pharma's 2010 results, pharma's Q3 results
GlaxoSmithKline has posted a third quarter loss after sales of its troubled diabetes drug Avandia and pandemic influenza products fell. …
GSK collaborates on rare genetic diseases
October 19, 2010Research and Development Fondazione San Raffaele, Fondazione Telethon, GlaxoSmithKline, Stem cells, gene therapy
GlaxoSmithKline has partnered with one of the biggest biomedical charities in Italy and the country’s largest private research institute to …
Digital Pharma: Pharma iPhone app update
October 15, 2010Medical Communications Astellas, Boehringer, Digital Pharma blog, GlaxoSmithKline, Lundbeck, Menarini, Nycomed, Pfizer, Servier, Teva, app, iphone
The ranks of pharma iPhone apps are increasing all the time and recent months have seen new additions from Teva, …
NICE rejects GSK Tyverb appeal
October 14, 2010Sales and Marketing GlaxoSmithKline, NICE, Tyverb
NICE’s independent appeal board has ruled the UK drug’s watchdog did not exceed its powers when issuing guidance on GlaxoSmithKline’s …
Avandia should still be on the market, says GSK
October 7, 2010Sales and Marketing Avandia, GlaxoSmithKline
GlaxoSmithKline believes European regulators were wrong to withdraw its diabetes drug Avandia from the market, but will not challenge their …
GlaxoSmithKline review leads to 121 layoffs in Cork
October 7, 2010Manufacturing and Production GlaxoSmithKline, Ireland, job cuts
GlaxoSmithKline has completed its review of a manufacturing facility in Ireland and concluded that it will have to shed 121 …
GSK takes stake in biotech spin-out
October 5, 2010Research and Development, Sales and Marketing Convergence, GlaxoSmithKline, funding
GlaxoSmithKline has taken a stake in a newly-launched biotech company in return for handing it two clinical compounds. The pharma …
GSK drops herpes vaccine
October 4, 2010Research and Development, Sales and Marketing GlaxoSmithKline, Simplirix, herpes, sexual health
Poor phase III results have forced GlaxoSmithKline to halt development of its Simplirix vaccine for women with genital herpes. The …
Extra phase II studies boost GSK’s Relovair
September 23, 2010COPD, GlaxoSmithKline, Relovair, asthma
GlaxoSmithKline has conducted additional phase II trials on its asthma/COPD drug Relovair to answer a number of safety and efficacy …
Digital Pharma: GSK takes drug information to Europe
September 21, 2010Medical Communications Digital Pharma blog, GlaxoSmithKline, digital patients
European patients can now get information on GlaxoSmithKline’s prescription medicines direct from the company through its expanded health.gsk.com website. The …
GSK workers in Ireland await review
September 20, 2010Manufacturing and Production, Research and Development GlaxoSmithKline, Ireland, job cuts
Workers at a GlaxoSmithKline facility in Ireland are anxiously awaiting the outcome of an official review of the operation amid …
GSK switches to subcutaneous route for antibody
September 16, 2010Research and Development Arzerra, Genmab, GlaxoSmithKline, ofatumumab
GlaxoSmithKline says it will switch development of a new antibody treatment to a subcutaneous injection, to make it more commercially …
Latest content
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
